Purpose: The aim of this study was to evaluate the effect of combined 68Ga and 18F-FDG PET/CT on treatment management for patients with pancreatic neuroendocrine tumor (PNET). Methods: Between January 2012 and April 2014, 49 consecutive patients with a cytologically and/or histologically proven diagnosis of PNET underwent combined 68Ga and 18FDG PET/CT on the same day. Results: The study group consisted of 21 males and 28 females with a median age of 59 years. Disease detection was achieved in 48 out of the 49 cases with 68Ga imaging, and in 36 of the 49 cases with 18FDG PET/CT. These results corresponded to sensitivities of 98% for 68Ga versus 73% for 18FDG PET/CT. Patients with NET-G1/NET-G2 had a positive 68Ga and negative 18FDG PET/CT in 13 cases, whereas both 68Ga and 18FDG PET/CT were positive in 27 cases. Patients with NEC-G3 were positive by both 68Ga and 18FDG PET/CT in 7 cases and positive only by 18FDG in 1 case. Another NEC-G3 patient was only positive by 68Ga PET/CT. The median Ki67 was 7% for 68Ga PET/CT-positive tumors and 10% for tumors with both 68Ga and 18FDG PET/CT positivity (p = 0.130). Half of the patients with a prevalent uptake of 18FDG (n = 7) had an NEC-G3 compared with 12% of patients with a prevalent uptake of 68Ga (p = 0.012). There were no significant differences between patients with positive 68Ga and those with positive 18FDG with regards to treatment choice. Conclusions: The association of 18FDG slightly increases sensitivity of 68Ga PET/CT alone in the diagnosis of PNET. A combined dual tracer PET/CT does not influence the choice of treatment strategy.

Journal Section:
Editor's choice
Keywords:
Neuroendocrine neoplasm, Pancreatic neuroendocrine tumor, Positron emission tomography, <sup>68</sup>Gallium, <sup>18</sup>FDG
1.
Oberg KE: The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol) 2012;24:282-293.
[PubMed]
https://doi.org/10.1016/j.clon.2011.08.006
2.
Treglia G, Castaldi P, Rindi G, et al: Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012;42:80-87.
[PubMed]
https://doi.org/10.1007/s12020-012-9631-1
3.
Kwekkeboom DJ, Kam BL, van Essen M, et al: Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-R73.
[PubMed]
https://doi.org/10.1677/ERC-09-0078
4.
Rahmim A, Zaidi H: PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 2008;29:193-207.
[PubMed]
https://doi.org/10.1097/MNM.0b013e3282f3a515
5.
Belhocine T, Foidart J, Rigo P, et al: Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 2002;23:727-734.
[PubMed]
https://doi.org/10.1097/00006231-200208000-00005
6.
Adams S, Baum RP, Hertel A, et al: Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 1998;19:641-647.
[PubMed]
7.
Kayani I, Bomanji JB, Groves A, et al: Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-2455.
[PubMed]
https://doi.org/10.1002/cncr.23469
8.
Naswa N, Sharma P, Gupta SK, et al: Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Clin Nucl Med 2014;39:e27-e34.
[PubMed]
https://doi.org/10.1097/RLU.0b013e31827a216b
9.
Ambrosini V, Campana D, Bodei L, et al: 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-673.
[PubMed]
https://doi.org/10.2967/jnumed.109.071712
10.
Klimstra DS, Modlin IR, Coppola D, et al: The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-712.
[PubMed]
https://doi.org/10.1097/MPA.0b013e3181ec124e
11.
Rindi G, Kloppel G, Alhman H, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
[PubMed]
https://doi.org/10.1007/s00428-006-0250-1
12.
Falconi M, Bartsch DK, Eriksson B, et al: ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012;95:120-134.
[PubMed]
https://doi.org/10.1159/000335587
13.
Zhernosekov KP, Filosofov DV, Baum RP, et al: Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741-1748.
[PubMed]
https://doi.org/10.2967/jnumed.107.040378
14.
Binderup T, Knigge U, Loft A, et al: Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010;51:704-712.
[PubMed]
https://doi.org/10.2967/jnumed.109.069765
15.
Reubi JC, Schar JC, Waser B, et al: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282.
[PubMed]
https://doi.org/10.1007/s002590050034
16.
Yang Z, Tang LH, Klimstra DS: Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 2011;35:853-860.
[PubMed]
https://doi.org/10.1097/PAS.0b013e31821a0696
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.